Biocept just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:
424B3 1 bioc-424b3_20160510.htm 424B3 bioc-424b3_20160510.htm Filed Pursuant to Rule 424 (b) (3) Registration No. 333-208683 3,774,122 Shares Common Stock This prospectus relates to the sale of up to 3,774,122 shares of our common stock by Aspire Capital Fund, LLC. Aspire Capital is also referred to in this prospectus as the selling stockholder. The prices at which the selling stockholder may sell the shares will be determined by the prevailing market price for t he shares or in negotiated transactions. We will not receive proceeds from the sale of the shares by the selling stockholder. However, we may receive proceeds of up to $15 million from the sale of our common stock to the selling stockholder, pursuant to a common stock purchase agreement entered into with the selling stockholder on December 21, 2015, including proceeds that we have already received thereunder. The selling stockholder is an “underwriter” within the meaning of the Securities Act of 1933, as amended. We will pay the expenses of registering these shares, but all selling and other expenses incurred by the selling stockholder will be paid by the selling stockholder. Our common stock is listed on The NASDAQ Capital Market under the ticker symbol “BIOC.” On May 9, 2016, the last reported sale price per share of our common stock was $0.85 per share. You should read this prospectus, together with additional information described under the headings “Incorporation of Certain Information by Reference” and “Where You Can Find More Information,” carefully before you invest in any of our securities. Investing in our securities involves a high degree of risk. See “Risk Factors” on page 5 of this prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The date of this pros
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Biocept makes a similar move, sign up!
Other recent filings from the company include the following:
On April - April 6, 2018
Biocept Just Filed Its Annual Report: 12. Net Loss per Co... - March 28, 2018